Here we present an alternative approach to block fatty acid oxidation in AML, namely by targeting the first step in the fatty acid oxidation—the fatty acid transporter CD36, with a drug-like small-molecule compound. The gene discussed is CD36; the disease is acute myeloid leukemia.